60岁及以下胰腺癌患者二代测序的临床相关性:全国性前瞻性队列研究
这项荷兰13家医院的全国前瞻性队列研究纳入318例≤60岁胰腺导管腺癌患者,评估肿瘤分子图谱的可行性与临床影响。全外显子组和全转录组测序在55.0%患者中完成,13.2%检出可操作变异,但仅26.2%的可操作变异患者接受了匹配治疗,提示分子检测成功率和临床转化均有限。
要点
- ≤60岁胰腺癌患者中55.0%完成全外显子组和全转录组测序,切除标本成功率高于活检标本。
- 13.2%患者检出可操作变异,KRAS野生型肿瘤中可操作靶点比例达92.3%。
- 仅26.2%的可操作变异患者接受匹配治疗,临床转化率有限。
核心结论
- ≤60岁胰腺癌患者完整分子图谱检测成功率为55%,可操作变异检出率13.2%,但仅3.5%患者实际接受匹配治疗,临床影响有限。
研究设计与样本
- 全国性前瞻性队列研究,2021年4月至2024年6月纳入荷兰13家医院318例≤60岁、任何分期和治療状态的胰腺导管腺癌患者。
- 对肿瘤FFPE标本进行全外显子组测序和全转录组测序,并由多学科分子肿瘤委员会每月审核结果。
主要发现
- 318例中88.7%(282/318)有适合测序的肿瘤样本,175例(55.0%)完成全外显子组和全转录组测序,88例(27.7%)仅完成全转录组测序。
- 切除标本完整分子分析成功率79%,活检标本为33%(P < .001)。
- 4%(13/318)患者发现癌症易感基因的未知胚系突变。
- 13.2%(42/318)检出可操作变异,在完成全外显子组和全转录组测序的患者中升至22.3%(39/175)。
- KRAS野生型肿瘤中92.3%(12/13)检出可操作靶点,但仅26.2%(11/42)可操作变异患者接受匹配治疗。
临床怎么用
- 对≤60岁胰腺癌患者可考虑分子检测,但需优先选择切除标本以提高测序成功率。
- KRAS野生型肿瘤应优先进行KRAS检测和更深入测序以寻找可操作靶点。
- 需扩大靶向治疗可及性以提升分子检测的临床转化率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Pancreatic ductal adenocarcinoma (PDAC) has limited therapeutic options and frequent resistance to standard treatments. This study evaluates the feasibility and clinical impact of comprehensive tumor molecular profiling in PDAC patients aged ≤ 60 years. METHODS: Nationwide prospective cohort study across 13 Dutch hospitals from April 2021 to June 2024. PDAC patients aged ≤ 60 at any disease stage were included regardless of treatment status. DNA and RNA from tumor samples were isolated from representative, formalin-fixed paraffin-embedded (FFPE) slides for whole-exome sequencing (WES) and whole-transcriptome sequencing (WTS). A multidisciplinary molecular tumor board reviewed results monthly. RESULTS: Among 318 patients, 88.7 % (282/318) had tumor samples suitable for sequencing. WES and WTS were completed in 175 patients (55.0 %), with WTS alone in 88 (27.7 %). Complete molecular analysis was more often successful in resection specimens than in biopsy samples (79 % vs 33 %; P < .001). Unknown germline mutations in cancer predisposition genes were identified in 4 % (13/318) of patients. Actionable alterations were detected in 13.2 % (42/318), rising to 22.3 % (39/175) among patients with WES and WTS. Actionable targets were found in 92.3 % (12/13) KRAS-wildtype tumors. Only 11 of 42 (26.2 %) patients received tailored therapies. CONCLUSIONS: Complete molecular profiling in PDAC patients ≤ 60 years showed moderate success (55 %) and limited clinical impact, with actionable findings in 13 % and therapy implementation in 3.5 %. Prioritizing KRAS testing and deeper sequencing in KRAS-wildtype tumors, alongside broader access to targeted therapies, may improve outcomes.
引用
- Strijk GJ, van Dongen JC, de Koning W, et al. Clinical relevance of next-generation sequencing in patients aged 60 years or younger with pancreatic cancer: A Nationwide prospective cohort study. Eur J Cancer. 2025. PMID: 41129983. doi:10.1016/j.ejca.2025.116065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。